1. Home
  2. CARM vs BGLC Comparison

CARM vs BGLC Comparison

Compare CARM & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CARM
  • BGLC
  • Stock Information
  • Founded
  • CARM 2016
  • BGLC 2017
  • Country
  • CARM United States
  • BGLC Malaysia
  • Employees
  • CARM N/A
  • BGLC N/A
  • Industry
  • CARM Biotechnology: Pharmaceutical Preparations
  • BGLC Medical Specialities
  • Sector
  • CARM Health Care
  • BGLC Health Care
  • Exchange
  • CARM Nasdaq
  • BGLC Nasdaq
  • Market Cap
  • CARM 12.2M
  • BGLC 10.7M
  • IPO Year
  • CARM N/A
  • BGLC N/A
  • Fundamental
  • Price
  • CARM $0.24
  • BGLC $5.63
  • Analyst Decision
  • CARM Hold
  • BGLC
  • Analyst Count
  • CARM 5
  • BGLC 0
  • Target Price
  • CARM $0.90
  • BGLC N/A
  • AVG Volume (30 Days)
  • CARM 447.9K
  • BGLC 3.1M
  • Earning Date
  • CARM 08-07-2025
  • BGLC 08-18-2025
  • Dividend Yield
  • CARM N/A
  • BGLC N/A
  • EPS Growth
  • CARM N/A
  • BGLC N/A
  • EPS
  • CARM N/A
  • BGLC N/A
  • Revenue
  • CARM $10,767,000.00
  • BGLC $9,551,559.00
  • Revenue This Year
  • CARM N/A
  • BGLC N/A
  • Revenue Next Year
  • CARM N/A
  • BGLC N/A
  • P/E Ratio
  • CARM N/A
  • BGLC N/A
  • Revenue Growth
  • CARM N/A
  • BGLC 4.01
  • 52 Week Low
  • CARM $0.14
  • BGLC $2.01
  • 52 Week High
  • CARM $1.27
  • BGLC $15.60
  • Technical
  • Relative Strength Index (RSI)
  • CARM 31.94
  • BGLC 52.39
  • Support Level
  • CARM $0.21
  • BGLC $5.21
  • Resistance Level
  • CARM $0.31
  • BGLC $5.72
  • Average True Range (ATR)
  • CARM 0.03
  • BGLC 0.35
  • MACD
  • CARM -0.00
  • BGLC -0.06
  • Stochastic Oscillator
  • CARM 23.64
  • BGLC 33.11

About CARM Carisma Therapeutics Inc.

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: